An Escalating Dose Regimen of Pegylated Interferon and Ribavirin in HCV Cirrhotic Patients Referred for Liver Transplant

Abstract

Using an escalating dose regimen of PEG-IFN alpha-2a and ribavirin, we achieved only a 13% sustained virological response in HCV cirrhotic pre-LT patients with an accompanying 9% risk of worsening liver function and 7% risk of death.